These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Adrenocortical carcinoma. Decker RA; Kuehner ME Am Surg; 1991 Aug; 57(8):502-13. PubMed ID: 1928992 [TBL] [Abstract][Full Text] [Related]
4. [Surgical strategy in the treatment of adrenal cortex cancer. Expanded and repeated interventions]. Borrelli D; Bergamini C; Borrelli A; Reddavide S; Lassig R; Valeri A Ann Ital Chir; 2003; 74(3):311-7. PubMed ID: 14677288 [TBL] [Abstract][Full Text] [Related]
5. [Local recurrence of non-functioning adrenocortical carcinoma 14 years following surgical treatment: a case report]. Ishida T; Tokunaga S; Ohkawa M; Hisazumi H; Sasano H Hinyokika Kiyo; 1993 Jun; 39(6):549-51. PubMed ID: 8337981 [TBL] [Abstract][Full Text] [Related]
6. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma? Dickstein G; Shechner C; Arad E; Best LA; Nativ O J Clin Endocrinol Metab; 1998 Sep; 83(9):3100-3. PubMed ID: 9745410 [TBL] [Abstract][Full Text] [Related]
9. [Malignant cortico-adrenal tumors with vena cava extension. Is surgical resection justified?]. Peix JL; Mancini F; Villard J; Van Box Som P Ann Chir; 1998; 52(4):357-63. PubMed ID: 9752470 [TBL] [Abstract][Full Text] [Related]
10. Metastatic adrenocortical carcinoma treated by repeated resection: a case report of long-term survival over 18 years. Sakamoto K; Ariyoshi A; Okazaki M Int J Urol; 1995 Mar; 2(1):50-2. PubMed ID: 7614407 [TBL] [Abstract][Full Text] [Related]
11. Complete remission of metastasized adrenocortical carcinoma under o,p'-DDD. Kornely E; Schlaghecke R Exp Clin Endocrinol; 1994; 102(1):50-3. PubMed ID: 8005209 [TBL] [Abstract][Full Text] [Related]
12. [Adrenal carcinoma. Clinical and anatomopathological prognostic factors]. Boneschi M; Erba M; Beretta L; Miani S; Bortolani EM Minerva Chir; 1998 Mar; 53(3):167-72. PubMed ID: 9617113 [TBL] [Abstract][Full Text] [Related]
13. [A case of adrenal cortical carcinoma]. Oida T; Souma T; Doi H; Hida S; Takasu K Hinyokika Kiyo; 2002 Nov; 48(11):667-70. PubMed ID: 12512139 [TBL] [Abstract][Full Text] [Related]
15. [Associated role of surgery and antimitotic o, p'-DDD treatment in hyperfunctioning adrenal cancers with diffuse metastases]. Perigli G; Borrelli D; Salvatore S; Cicchi P; Burci P Chir Ital; 1981 Feb; 33(1):122-34. PubMed ID: 6167374 [TBL] [Abstract][Full Text] [Related]
16. Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Hermsen IG; Gelderblom H; Kievit J; Romijn JA; Haak HR Eur J Endocrinol; 2008 Jun; 158(6):911-9. PubMed ID: 18505909 [TBL] [Abstract][Full Text] [Related]
17. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. Gonzalez RJ; Tamm EP; Ng C; Phan AT; Vassilopoulou-Sellin R; Perrier ND; Evans DB; Lee JE Surgery; 2007 Dec; 142(6):867-75; discussion 867-75. PubMed ID: 18063070 [TBL] [Abstract][Full Text] [Related]
18. [Carcinoma of the adrenal cortex]. Hamborg B; Frey H; Bøhmer T; Norman N Tidsskr Nor Laegeforen; 1990 Mar; 110(8):956-9. PubMed ID: 2321225 [TBL] [Abstract][Full Text] [Related]
19. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757 [TBL] [Abstract][Full Text] [Related]